Remimazolam is an ultra-short acting benzodiazepine used intravenously for induction and maintenance of sedation for adults undergoing short term procedures not requiring general anesthesia. Remimazolam sedation has not been associated with serum aminotransferase elevations and has not been linked to cases of clinically apparent liver injury. It is grouped under the following drug class(es): Schedule IV controlled substances. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include remimazolamum, Byfavo (TN) and CNS 7056. It is listed as a controlled drug substance (Schedule IV). Its PubChem CID is 9867812.
Remimazolam
| CAS No | 308242-62-8 |
|---|---|
| Molecular Formula | C21H19BrN4O2 |
| Molecular Weight | 439.3 g/mol |
| Synonyms | methyl 3-[(4S)-8-bromo-1-methyl-6-pyridin-2-yl-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Remimazolam is an ultra-short acting benzodiazepine used intravenously for induction and maintenance of sedation for adults undergoing short term procedures not requiring general anesthesia.
The listed CAS number is 308242-62-8.
The listed molecular formula is C21H19BrN4O2.
The listed molecular weight is 439.3 g/mol.
methyl 3-[(4S)-8-bromo-1-methyl-6-pyridin-2-yl-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate.
The source lists remimazolamum, Byfavo (TN) and CNS 7056.